截至发稿，诺诚健华收盘价 29.10 元，涨幅 4.49%，成交额 3.83 亿元，换手率 4.94%，量比 0.83，日内振幅 8.55%；前期高点 31.91 元附近存在短期价格压制。

基本面数据

2025 年：营收 23.7 亿元，同比大幅增长 135%；归母净利润 6.42 亿元，同比增幅 246%，营收、盈利实现爆发式提升。

2026 年一季度：归母净利润 1.06 亿元，同比大增 488.93%，单季盈利维持超高增速。

Wind 机构一致预期

2026 年营收 23.6 亿元（同比 - 0.51%）、净利润 2.27 亿元（同比 - 64.7%）；

2027 年营收 26.2 亿元（同比 + 10.8%）、净利润 2.00 亿元（同比 - 11.7%）。

主营业务结构

药品销售营收占比 60.73%，技术授权业务占 38.07%，研发服务、检测服务分别占 1.11%、0.09%，主营创新药商业化销售、医药技术授权合作。

以上信息基于公开数据整理，不构成投资建议。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.